This risk appears to be higher in people with a history of pancreatitis or risk factors for it, such as heavy alcohol use or gallstones
Both the GLP-1 stomach injury lawsuits and Ozempic vision loss lawsuits have been consolidated into two separate MDLs, or multidistrict litigations, being overseen by U.S
Thats where GLP-1 medications, like Ozempic and Wegovy, come in
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
These symptoms can lead to reduced fluid intake and increased fluid loss, both of which concentrate the urine and may increase the risk of crystal formation and kidney stone development